PepGen

PepGen, Inc. is a biotechnology company dedicated to advancing next-generation oligonucleotide therapies for neuromuscular diseases. PepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform is designed to safely and effectively target the root causes of rare genetic disorders such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). In preclinical studies, PepGen’s enhanced delivery peptides have successfully demonstrated cell penetration and the ability to deliver therapeutic candidates to various tissue types, including cardiac tissue.